WHO ICTRP trial
A rotation study of different albuminuria lowering drug classes to study…
EUCTR2017-004641-25-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2017-004641-25-ES |
|---|---|
| Public title | A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetic and non diabetic Chronic Kideny Disease |
| Scientific title | Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation. - ROTATE 3 |
| Primary sponsor | University Medical Center Groningen |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Spain;Netherlands;Italy |
| Conditions | Proteinuric Kidney disease;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] |
| Interventions | Trade Name: Forxiga Product Name: Dapaglifozin Pharmaceutical Form: Tablet INN or Proposed INN: Dapagliflozin CAS Number: 461432-26-8 Other descriptive name: DAPAGLIFLOZIN Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Nov 4, 2019 |
| Target size | 46 |
| Secondary IDs | 201700823 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: